TSVT

Investor Moves

Name	Value	Action	Change	Price	Current Price
Ken GriffinCitadel Advisors $-154.6K ExitQ2 2025 $155k -- $5.00
Steven CohenPoint72 $-913.3K ExitQ1 2025 $913k -- $5.00
Ken GriffinCitadel Advisors $59.0K AddQ1 2025 $59k -- $5.00
Ken GriffinCitadel Advisors $-118.3K TrimQ4 2024 $118k -- $5.00
Ken GriffinCitadel Advisors $60.7K AddQ3 2024 $61k -- $5.00

Insider Trades

Name	Value	Action	Price	Current Price
Baird William D IIIDirector, Officer: President And CEO $25k5.1k shares SellMar 17, 2025 $4.95 $5.00
Eatwell VictoriaChief Financial Officer $13k2.6k shares SellMar 17, 2025 $4.95 $5.00
Snow JessicaChief Operating Officer $11k2.3k shares SellMar 17, 2025 $4.95 $5.00
Kynam Global Healthcare Master Fund, LP10 Percent Owner $25M5.1M shares SellMar 11, 2025 $4.93 $5.00
Snow JessicaSee Remarks $5.1k1.8k shares SellJan 6, 2025 $2.79 $5.00
Leschly NickDirector $252k86k shares SellJan 3, 2025 $2.94 $5.00

Trade TSVT

About 2seventy bio, Inc.

2seventy bio, Inc. operates as a biotechnology firm specializing in cell and gene therapies, with a primary mission to discover, develop, and commercialize advanced cancer treatments within the U.S. Its pipeline notably includes idecabtagene vicleucel, marketed as ide-cel or Abecma, and bb21217, both of which are CAR-T cell therapeutic candidates specifically designed to address multiple myeloma. The company also maintains a strategic partnership with Bristol-Myers Squibb Company. Founded in 2021, its corporate headquarters are situated in Cambridge, Massachusetts.

CEO: William D. Baird III,
IPO Date: Nov 3, 2021

Market Data

Open: $5.00
High: $5.00
Low: $5.00
Volume: 1.2M
Avg Volume: 1.5M
52W High: $5.30
52W Low: $2.29

Valuation

Market Cap: $266.1M
Enterprise Value: $413.5M
Dividend Yield: 0.00%

Financials

Free Cash Flow: -$85.7M
Revenue: $37.9M
Net Income: -$57.2M
Cash: $71.2M
Debt: $243.7M

Events

EarningsNov 10